Abstract
Recombinant human endostatin (rhEndostatin) is uniquely able to target neovascular endothelial cells (ECs) and has the potential for antiangiogenetic and antitumor activities. In this review, we explore experimental approaches and clinical trials focusing on drug delivery of endostatin. Continued endostatin therapy can maintain tumors in a state of dormancy, and no signs of drug-induced resistance have been observed. Prolonged delivery of endostatin may be achieved by using pumps (mini-osmotic pumps) or cell encapsulation systems. The largest benefit from rhEndostatin is expected when drug delivery of rhEndostatin is begun as early as possible. Although endostatin has shown promise in controlling tumor neovasculature, a major problem in pharmacotherapy is the side effects of constant drug administration and the limited half-life of antiangiogenic proteins. Gene therapy offers the advantages of maximizing cost effectiveness and maintaining sustained levels of antiangiogenic factors, which may enhance antitumor efficacy. Therefore, we have investigated recent advances in gene delivery of endostatin for cancer treatment. In recent years, preclinical and clinical data have demonstrated the synergistic effects of rhEndostatin combin...Continue Reading
Citations
Sep 29, 2010·Molekuliarnaia biologiia·Wen XuKe Yao
Jan 10, 2009·BMC Cancer·Michael W RetskyIsaac D Gukas
Dec 21, 2010·International Journal of Nanomedicine·Sanyuan Hu, Yangde Zhang
Aug 17, 2011·International Journal of Nanomedicine·Weijie Chen, Sanyuan Hu
Apr 17, 2009·Expert Opinion on Biological Therapy·Michalis V Karamouzis, Stergios J Moschos
Feb 13, 2016·Frontiers in Pharmacology·Sylvie Ricard-Blum, Sylvain D Vallet
Apr 5, 2011·Biomaterials·Xiao LuWan-Tai Yang
Sep 14, 2010·Wiley Interdisciplinary Reviews. Systems Biology and Medicine·Ambra Pozzi, Roy Zent
Feb 7, 2017·Drug Delivery·Rui-Lin DingQing-Lian Wen
Aug 7, 2013·Paediatric Drugs·Edwin A Lomotan, Denise Dougherty
Sep 2, 2017·Nuclear Medicine Communications·Chuanwang MiaoXudong Hu
Feb 19, 2020·Thoracic Cancer·Ma HonglianChen Ming
Dec 8, 2017·Oncotarget·Jing AiKe Yao
Aug 11, 2018·Medicine·Difei YaoHaibin Dai